Biomarkers for a less invasive strategy to predict children with eosinophilic esophagitis

Helena Thulin1,2, Ladan Mansouri1, Maria Altman2,3

  • 1Department of Clinical Science and Education, South Hospital, Karolinska Institutet, Stockholm, Sweden.

Allergy
|August 19, 2024
PubMed

Insights

Researchers identified novel biomarkers for diagnosing eosinophilic esophagitis (EoE). A panel of biomarkers and symptoms effectively distinguishes active EoE, remission, and healthy individuals, offering a less invasive diagnostic approach.

Area of Science:

  • Allergy and Immunology
  • Pediatric Gastroenterology
  • Biomarker Discovery

Background:

  • Eosinophilic esophagitis (EoE) lacks noninvasive diagnostic and monitoring biomarkers.
  • Current diagnostic methods for EoE can be invasive.
  • There is a need for reliable biomarkers to assess EoE status in children.

Purpose of the Study:

  • To evaluate the diagnostic potential of 20 serum and saliva biomarkers in pediatric EoE patients.
  • To identify a panel of biomarkers capable of differentiating active EoE, EoE in remission, and healthy controls.
  • To assess the utility of biomarkers in monitoring disease progression and remission.

Main Methods:

  • Analysis of serum and saliva biomarkers including absolute eosinophil count (AEC), eosinophil-derived neurotoxin (EDN), specific IgE (sIgE), and IgG4 (sIgG4) antibodies.
  • Evaluation of 15-hydroxyeicosatetraenoic acid (15(S)-HETE).
  • Longitudinal assessment in a subset of patients to track biomarker changes during disease course.

Main Results:

  • Elevated levels of AEC, EDN, 15(S)-HETE, sIgG4, and sIgE were observed in active EoE compared to healthy individuals.
  • A combination of biomarkers (AEC, EDN, sIgE to egg white and wheat) and symptoms achieved an AUC of 0.92 for distinguishing between active EoE, remission, and healthy groups.
  • Biomarker panel demonstrated 88% sensitivity and 100% specificity in distinguishing EoE (active and remission) from healthy individuals.

Conclusions:

  • A novel panel of biomarkers, combined with symptoms, effectively discriminates between active EoE, EoE in remission, and healthy states.
  • These findings support the development of less invasive diagnostic methods for pediatric EoE.
  • The identified biomarkers show potential as a surveillance tool for monitoring pediatric EoE patients.
Abstract